TheraCyte
TheraCyte is a private, for-profit manufacturer of cell encapsulation systems headquartered in San Clemente, California, serving research and therapeutic cell-delivery applications through immunoisolation device technology.
- Company typePrivate
- Founded-
- HeadquartersSan Clemente, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What TheraCyte does
TheraCyte is a privately held, for-profit company headquartered in San Clemente, California, United States. According to the firmographic record, the company manufactures cell encapsulation systems — devices designed to encapsulate therapeutic cells within a semi-permeable membrane, typically for immunoisolation and controlled delivery in cell-based therapies. Cell encapsulation systems of this type are generally deployed as combination-style medical devices in research, preclinical, or clinical-stage cell therapy programs (for example, pancreatic islet encapsulation for diabetes). The precise product specifications, pipeline targets, and regulatory positioning are not documented in the input source.
No further detail on the company's product line, revenue model, customer base, partnerships, intellectual property, leadership, funding history, or operating geographies is present in the provided source material. The company website (theracyte.com) was captured during this exercise only as a verification/loading page and did not return substantive company content. Operating status is recorded as "operating" by default, but no corroborating evidence — such as management team listings, certifications, regulatory filings, or disclosed financial events — is available. Any conclusions about the company's commercial stage, scientific milestones, or strategic direction cannot be drawn from the input and require direct verification.
TheraCyte firmographics
Firmographics- Name
- TheraCyte
- Website
- https://theracyte.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- TheraCyte is a private, for-profit manufacturer of cell encapsulation systems headquartered in San Clemente, California, serving research and therapeutic cell-delivery applications through immunoisolation device technology.
- Ownership category
- akta.pro rank
TheraCyte industry classification
Industry- Product category
- Biomedical Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)
- akta.pro secondary industry
- Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)
Keywords
Where TheraCyte is headquartered
LocationHeadquarters
- HQ city
- San Clemente
- HQ country
- United States
- HQ region
- North America
Markets served
TheraCyte business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Operations
TheraCyte product offering
Product offeringCore offering
TheraCyte manufactures cell encapsulation systems designed for therapeutic and research applications. The company's core offering centers on physical encapsulation devices that house cells for medical and biotechnological use. TheraCyte operates as a product-based manufacturer based in San Clemente, California, United States.
Differentiator
Problem solved
Functional benefit
Products and services
- Cell Encapsulation Systems
Companies that use TheraCyte
Customer profileIdeal customer profiles1 record
TheraCyte technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
TheraCyte competitors and assessment
Company assessmentDirect peers
- Sernova: Developer of the Cell Pouch and related encapsulation technologies for therapeutic cell transplantation, including an active Type 1 diabetes program. Closely matches TheraCyte's encapsulation-device-plus-therapeutic-cells model.
- ViaCyte: Pioneer in encapsulated stem-cell-derived islet therapies for Type 1 and Type 2 diabetes. Directly comparable to TheraCyte as a developer of cell-encapsulation-based therapeutics targeting insulin-dependent diabetes.
- Beta-O2 Technologies: Developer of the Bio-artificial Pancreas (ßAir) macroencapsulation device for Type 1 diabetes. Competes in the same niche of implantable cell-encapsulation devices for endocrine disease.
- Sigilon Therapeutics: Engineered cells combined with proprietary immuno-protective encapsulation spheres. Directly comparable in building encapsulated cell therapies across metabolic and other indications.
- Defymed: Developer of MailPan and other implantable bio-artificial organ devices for cell therapy delivery. Directly competes with TheraCyte in macroencapsulation hardware for cell transplantation.
Emerging players
- Islet Sciences: Historically closely tied to TheraCyte's intellectual-property lineage; comparable small-cap peer focused on encapsulated islet cell transplantation for diabetes. Website not reliably known.
Broad incumbents
- Vertex Pharmaceuticals (Cell Therapy): Through its acquisition of ViaCyte/Semma, Vertex is developing encapsulated islet cell therapies for Type 1 diabetes. A large incumbent with overlapping interest in the same encapsulation-driven cell therapy modality.
Regional players
- Diatranz Otsuka Japan (Diabcell / Otsuka): Japan-based developer of encapsulated pig islet cell therapy for diabetes. Comparable cell-encapsulation modality, focused primarily in the Japanese market.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat2 records
Key risks4 records
Key highlights3 records
Customer concentration
TheraCyte social profiles
Digital presenceTheraCyte financial estimates
Financial estimateRevenue estimate
Valuation estimate
TheraCyte leadership team
Management profileNumber of profiles
TheraCyte funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TheraCyte M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TheraCyte
What does TheraCyte do?
TheraCyte manufactures cell encapsulation systems designed for therapeutic and research applications. The company's core offering centers on physical encapsulation devices that house cells for medical and biotechnological use. TheraCyte operates as a product-based manufacturer based in San Clemente, California, United States.
When was TheraCyte founded?
TheraCyte was founded in -1. It employs 1 to 10 people.
Where is TheraCyte based?
TheraCyte is headquartered in San Clemente, United States, in the North America region.
Who are TheraCyte's main competitors?
Direct peers on record are Sernova, ViaCyte, Beta-O2 Technologies, Sigilon Therapeutics and Defymed. Islet Sciences is listed as an emerging player. Vertex Pharmaceuticals (Cell Therapy) is listed as a broad incumbent. Diatranz Otsuka Japan (Diabcell / Otsuka) is listed as a regional player.
Does TheraCyte have an API?
No public API is recorded for TheraCyte.
What industry is TheraCyte in?
TheraCyte's product category is Biomedical Devices. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish), with a secondary code of HLAAABAH, Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables). Its NAICS code is 3391 and its SIC code is 3841.